Skip to main content

Advertisement

Table 6 Determination of DPPH scavenging activity of eugenol derivatives

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound/sample IC50 (µg/mL)a Sr. no IC50 (µg/mL)a
5a 9.152 ± 0.063 13a 20.66 ± 0.032
5b 8.304 ± 0.073 13b 12.47 ± 0.014
7 9.786 ± 0.012 13c 16.04 ± 0.026
9a 9.514 ± 0.017 13d 14.88 ± 0.018
9b 9.293 ± 0.028 16 27.70 ± 0.023
11 11.21 ± 0.044 17 31.30 ± 0.014
Eugenol 10.29 ± 0.011 l-Ascorbic acid 8.58 ± 0.009
  1. aValue are expressed as mean ± SEM, n = 3